Buying hash Velenje
Buying hash VelenjeBuying hash Velenje
__________________________
📍 Verified store!
📍 Guarantees! Quality! Reviews!
__________________________
▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼
▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲
Buying hash Velenje
These datasets underpin the analysis presented in the agency's work. Most data may be viewed interactively on screen and downloaded in Excel format. All countries. Topics A-Z. The content in this section is aimed at anyone involved in planning, implementing or making decisions about health and social responses. Best practice. We have developed a systemic approach that brings together the human networks, processes and scientific tools necessary for collecting, analysing and reporting on the many aspects of the European drugs phenomenon. Explore our wide range of publications, videos and infographics on the drugs problem and how Europe is responding to it. All publications. More events. More news. We are your source of drug-related expertise in Europe. We prepare and share independent, scientifically validated knowledge, alerts and recommendations. About the EUDA. Cannabis remains by far the most commonly consumed illicit drug in Europe. On this page, you can find the latest analysis of the drug situation for cannabis in Europe, including prevalence of use, treatment demand, seizures, price and potency, harms and more. European Drug Report — home. The drug situation in Europe up to Drug supply, production and precursors. Synthetic stimulants. Heroin and other opioids. Other drugs. New psychoactive substances. Injecting drug use in Europe. Drug-related infectious diseases. Drug-induced deaths. Opioid agonist treatment. Harm reduction. However, both the level of use and trends in use reported in recent national data appear heterogeneous see Prevalence and patterns of cannabis use , below. At the same time, there is an ongoing debate on how best to respond to the use of this drug, with some countries modifying their regulatory approach. We are also seeing significant developments in the cannabis market. Taken together, this all means that there remains a pressing need to understand better the potential harms associated with different patterns of cannabis consumption and the implications this raises for policy and practice. Around 1. Cannabis use can cause or exacerbate a range of physical and mental health problems, including chronic respiratory symptoms, cannabis dependence and psychotic symptoms. In addition, studies have found that regular cannabis use can be associated with poorer educational achievement and an increased risk of involvement with the criminal justice system. Problems are most associated with early onset of use, high-potency products and more regular and long-term patterns of use. There remains, however, a need to understand better the kinds of problems experienced by cannabis users, as well as what are appropriate referral pathways and effective treatment options for those with cannabis-related problems. Cannabis is reported to be responsible for more than one third of all drug treatment admissions in Europe. This finding is difficult to interpret, in part because of the wide variety of interventions provided to cannabis users, which may include brief interventions or directive referrals from the criminal justice system. Further work is needed to understand better the kind of services offered to those with cannabis problems. However, the information that does exist would suggest that psychosocial treatments, such as cognitive behavioural therapy, are commonly offered and that e-health online interventions appear to be increasingly available. Evaluating the risk of harm in this area is complicated by the apparently increasing range of cannabis-based products potentially available to consumers, which can include edibles, high-potency products and various derivatives. This diversity can have implications for the risk of an individual experiencing problems with their cannabis use and is therefore an area that requires greater research and regulatory attention. Overall, the number of people reported as entering treatment for cannabis problems for the first time remained relatively stable until , before declining during the pandemic, and not returning to pre-pandemic levels in most EU Member States by see Treatment entry for cannabis use , below. A caveat here is that data quality and coverage issues mean that this observation must be interpreted with caution. Seizures of cannabis products overall continued to be at historically high levels in , indicating the high availability of this drug see Cannabis market data , below. However, the total quantity of cannabis resin seized in the European Union dropped significantly, largely due to a decrease in seizures reported by Spain. It is possible that this may reflect an adaptation in supply routes by those involved in trafficking cannabis resin from North Africa to Europe as a response to anti-trafficking measures taken by Spanish authorities. In this context, it is also interesting to note that since the volume of herbal cannabis seized has increased significantly in Spain. However, it is important to note that significant cannabis production also takes place elsewhere in the European Union. Recent large seizures highlight the role Spain continues to play as a transit country for resin intended for the European market. In , for example, Spanish authorities seized 22 tonnes of cannabis resin concealed in fake tomato packaging suspected of being destined for trafficking to France see Figure 2. Although new products and forms of this drug are available, herbal cannabis and cannabis resin remain the most commonly available forms. While the quantities of cannabis resin seized in the European Union are greater than those of herbal cannabis, this is thought to reflect the greater vulnerability of cannabis resin to interdiction measures in cross-border trafficking, rather than availability or use. The information available suggests that herbal cannabis is the more commonly available form of the drug in most countries. Herbal cannabis may be grown near to its intended consumer market, and this may reduce the risk of detection. This is very high by historical standards, potentially creating elevated health risks, particularly when associated with early onset of use. Some worrying new developments in the detection of cannabis seizures entering Europe may indicate that trafficking routes are diversifying and creating a growing challenge for interdiction efforts. These include, for example, the seizure of 4 tonnes of cannabis resin originating from Pakistan in the port of Antwerp, Belgium. Moreover, this is evidence that Morocco is not the only source of resin for the European cannabis market. Some EU Member States reported the trafficking of cannabis through postal systems and, increasingly, through commercial air travel, sometimes linked to the United States and Canada. There are indications that larger quantities of herbal cannabis may be shipped from North America via maritime routes. This, alongside the appearance of new forms of the drug, raises concerns that developments in regulated cannabis markets outside Europe may increasingly have implications for the availability of this drug within the European Union in the future. The diversity of cannabis products available in Europe is increasing. This is true for the illicit drug market. It is also true for the consumer market, where products are appearing that contain low levels of THC, or other substances that may be derived from the cannabis plant such as CBD, or both. On the illicit drug market, the availability of high-potency extracts and edibles is of particular concern and has been linked to acute drug-toxicity presentations in hospital emergency departments. In addition, there are concerns that some products sold on the illicit market as cannabis may be adulterated with potent synthetic cannabinoids. For more information on these synthetic cannabinoids, see New psychoactive substances — the current situation in Europe. Some semi-synthetic cannabinoids have also appeared recently on the commercial market in parts of Europe. These are substances thought to be produced from cannabidiol extracted from low-THC cannabis hemp , not controlled under the international drug conventions. While knowledge of the effects of HHC in humans is limited, concerns have been raised as studies have emerged, including some reports of links to psychosis. Many of the cases involved young people, including children, who had consumed edibles, such as gummy bears. The European policy approach to cannabis is also becoming more diverse, as some EU Member States are considering or changing their policy approach to recreational cannabis use, creating various forms of access to cannabis resin and herb products. In December , Malta legislated for home growing and cannabis use in private, alongside non-profit communal growing clubs. In July , Luxembourg legislated to permit home growing and use in private, and in February , Germany legislated to allow home growing and non-profit cannabis growing clubs. Czechia has also announced plans for a regulated and taxed distribution system. In addition, non-EU Switzerland has started to authorise pilot trials of sales or other distribution systems for specific residents in certain cities. The Netherlands is also reviewing its approach in this area. The cultivation, sale and possession of cannabis remain criminal offences in the Netherlands. A concern with this approach is that cannabis is still necessarily supplied from the illegal market, and criminal groups therefore benefit from this trade. To address this issue, the Netherlands is piloting a model for a closed cannabis supply chain in 10 municipalities, with cannabis produced in regulated premises being made available for sale in cannabis coffeeshops. This data explorer enables you to view our data on the prevalence of cannabis use by recall period and age range. You can access data by country by clicking on the map or selecting a country from the dropdown menu. Prevalence data presented here are based on general population surveys submitted to the EMCDDA by national focal points. For the latest data and detailed methodological information please see the Statistical Bulletin Prevalence of drug use. Graphics showing the most recent data for a country are based on studies carried out between and Prevalence estimates for the general population: age ranges are and for Germany, Greece, France, Italy and Hungary; and for Denmark, Estonia and Norway; for Malta; for Sweden. In , of the 51 cities with comparable data, 20 reported an annual increase in the cannabis metabolite THC-COOH in wastewater samples, while 15 reported a decrease Figure 2. In most cities, sampling was carried out over a week between March and May Apart from the trends, data are for all treatment entrants with cannabis as the primary drug — or the most recent year available. Trends in first-time entrants are based on 25 countries. Only countries with data for at least 5 of the 6 years are included in the trends analysis. Missing values are interpolated from adjacent years. Because of disruptions to services due to COVID, data for , and should be interpreted with caution. Missing data were imputed with values from the previous year for Spain and France and Germany Price and potency: mean national values — minimum, maximum and interquartile range. Countries vary by indicator. Show source tables. The complete set of source data for the European Drug Report including metadata and methodological notes is available in our data catalogue. A subset of this data, used to generate infographics, charts and similar elements on this page, may be found below. Prevalence of drug use data tables including general population surveys and wastewater analysis all substances. Other data tables including tables specific to cannabis. Homepage Quick links Quick links. GO Results hosted on duckduckgo. Main navigation Data Open related submenu Data. Latest data Prevalence of drug use Drug-induced deaths Infectious diseases Problem drug use Treatment demand Seizures of drugs Price, purity and potency. Drug use and prison Drug law offences Health and social responses Drug checking Hospital emergencies data Syringe residues data Wastewater analysis Data catalogue. Selected topics Alternatives to coercive sanctions Cannabis Cannabis policy Cocaine Darknet markets Drug checking Drug consumption facilities Drug markets Drug-related deaths Drug-related infectious diseases. Recently published Findings from a scoping literature…. Penalties at a glance. Frequently asked questions FAQ : drug…. FAQ: therapeutic use of psychedelic…. Viral hepatitis elimination barometer…. EU Drug Market: New psychoactive…. EU Drug Market: Drivers and facilitators. Statistical Bulletin home. Quick links Search news Subscribe newsletter for recent news Subscribe to news releases. This make take up to a minute. Once the PDF is ready it will appear in this tab. Sorry, the download of the PDF failed. Table of contents Search within the book. Search within the book Operator Any match. Exact term match only. Prevalence and patterns of cannabis use Based on the most recent surveys Figure 2. Among to year-olds, an estimated It is estimated that around 1. Among to year-olds, an estimated 2. Trends in cannabis use at the national level appear mixed. Of the countries that have produced surveys since and reported confidence intervals, 3 reported higher estimates, 8 were stable and 2 reported a decrease compared with the previous comparable survey. This data source also indicates that consumers may be commonly using more than one form of this drug. Figure 2. Prevalence of cannabis use in Europe This data explorer enables you to view our data on the prevalence of cannabis use by recall period and age range. Users entering treatment for cannabis in Europe. Main subject. Target audience. Publication type. European Drug Report main page. On this page.
Bus schedule
Buying hash Velenje
These datasets underpin the analysis presented in the agency's work. Most data may be viewed interactively on screen and downloaded in Excel format. All countries. Topics A-Z. The content in this section is aimed at anyone involved in planning, implementing or making decisions about health and social responses. Best practice. We have developed a systemic approach that brings together the human networks, processes and scientific tools necessary for collecting, analysing and reporting on the many aspects of the European drugs phenomenon. Explore our wide range of publications, videos and infographics on the drugs problem and how Europe is responding to it. All publications. More events. More news. We are your source of drug-related expertise in Europe. We prepare and share independent, scientifically validated knowledge, alerts and recommendations. About the EUDA. Key findings and threat assessment. Global context. Trafficking and supply. Retail markets. Criminal networks. Actions to address current threats and increase preparedness. The affordability of drugs is a measure that incorporates drug purity or potency and accounts for differing national economic conditions, as quantified in the price level indices see Groshkova et al. Using affordability as a measure allows a more sophisticated comparison of retail drug markets across countries and over time. Source: The source data for this graphic is available in the source table on this page. Meanwhile the retail price of resin products has, on average, remained stable during the same year period. Several developments already raised in this report have likely contributed to the increase in resin potency. These include the introduction of new cannabis strains and new cultivation and resin extraction techniques in Morocco see Section Cannabis resin production outside the EU. In addition, it is also possible that the amount of high-potency cannabis resin produced in Europe is increasing. These recent trends seem to confirm a finding reported in the previous edition of this report EMCDDA and Europol, , namely that cannabis resin may have become a more attractive product to some consumers in the EU, especially for those who seek high-potency cannabis products. Data on the prevalence of cannabis use, expressed in estimated numbers of users during the last year, may be viewed as an indicator of the location and approximate size of retail markets. Historically, cannabis has been the most used illicit drug in Europe, with currently around 84 million adults in the European Union aged , or As is the case with other drugs, the majority of cannabis users in Europe are males, who on average are twice as likely to report use as females. Overall, the prevalence of cannabis use in Europe appears to have remained stable over the past decade, although prevalence of use has increased in some of the countries that already had the highest rates of use, such as Croatia, Czechia, the Netherlands and Spain. Recent trends based on data from 15 countries that have conducted surveys on last-year cannabis use since indicate that levels of use have increased in four countries, remained stable in six countries and decreased in five countries. However, it appears to have affected patterns of use, with more frequent herbal cannabis users consuming more and infrequent users consuming less, on average. This trend was less marked for cannabis resin see Section How cannabis products are retailed in Europe. The most recent data available on last-year use indicate that the largest retail markets for herbal cannabis and cannabis resin continue to be located in western and southern Europe. Young adults make up the majority of last-year cannabis users in Europe, representing an estimated Germany and Spain follow, with 3. In terms of estimated total numbers of cannabis users, Czechia and Poland appear to be the largest retail markets in the Eastern part of the EU, with an estimated 0. It is estimated that around 3. Cannabis prevalence data do not discriminate between the different products used. These proportions are indicative as the EWSD is not representative of the entire European population. In wastewater analysis, cannabis use is estimated by measuring its main metabolite, THC-COOH, which is the only suitable biomarker found so far, although it is excreted in low percentages Causanilles et al. There are several challenges and uncertainties in the wastewater analysis of THC-COOH, related to factors such as the analytical measurements and poorly understood excretion rates Bijlsma et al. In addition, this type of analysis is not able to discriminate between the different cannabis products consumed. Overall, research to develop alternative biomarkers is needed and caution is required when interpreting trends based on THC-COOH loads in wastewater. A stable or decreasing trend in the THC-COOH loads was observed for almost all of the 23 cities with available data for the period. In countries with multiple study locations, no marked differences were found in the THC-COOH loads when comparing large and small cities. Wastewater analysis can also detect fluctuations in patterns of illicit drug use across the week. In summary, the wastewater data indicate that, unlike the use of other drugs, such as cocaine EMCDDA, a , the European cannabis market is relatively stable overall since THC-COOH is present in both large and small urban areas and evidence of use is distributed evenly over the week. A further data source pointing to overall stability in the cannabis market is that of treatment demand for cannabis use problems. Based on the data available from 25 countries, the numbers entering specialised drug treatment for cannabis problems in Europe remained stable between and On average, clients entered treatment for cannabis problems every year during those four years. Similarly, an average of 58 people a year entered treatment for the first time in their lives during that period, with a 1. However, the number of treatment entrants declined noticeably in This is indicative of how the COVID pandemic affected treatment provision and demand as well as the monitoring of these services across Europe. While the numbers entering treatment increased slightly in , they still remained below the levels. The lack of rebound in treatment entries for cannabis problems in to pre-pandemic levels may be related to several factors. As a consequence, help-seeking and the ability to access services remained subdued. In addition, services continued to operate within strict infection prevention conditions, which reduced treatment capacity and intake. The data available may also mask a greater use of tele-medicine during this period, which was not captured by the treatment demand indicator. Finally, there may have also been a natural reduction in treatment demand due to reduced use of cannabis during the pandemic among some groups. Note: Trends in first-time entrants are based on data from 25 countries. Only countries with data for at least five of the six years are included in the trends analysis. Missing values are interpolated from adjacent years. Because of disruptions to services due to COVID, data for and should be interpreted with caution. Missing data were imputed from values for the previous year for Spain and France and Germany Since the total number of herbal cannabis seizures in Europe has exceeded those involving resin, and this continued to be the case in This appears to confirm that herbal cannabis is more widely consumed than cannabis resin in Europe. The majority of seizures of the two main cannabis products reported in Europe, namely herbal cannabis and cannabis resin, are probably confiscated on retail markets since they involve amounts of grams or less. In a context of consistently high drug availability at the retail level, a finite, but constant, level of law enforcement resources deployed to police illicit cannabis markets has likely influenced the relative stability in numbers of seizures. It is therefore probable that if more, or less, law enforcement resources were available to police these retail markets, seizure trends would vary commensurately. Both of these figures are underestimates since no data are available for from countries that usually report large numbers of seizures, such as France and Germany. By comparison, the total number of cocaine seizures, the second largest drug market in Europe, was estimated at 71 in Europe that same year. These countries thus have a substantial impact on overall seizure trends in Europe. Some of the overall reduction in cannabis seizures may be due to fewer police resources being focused on enforcing drug laws at the retail level in , as officers were mobilised to enforce COVID restrictions. In addition, prolonged lockdown periods likely drove many cannabis users and dealers out of public spaces. Although the use of herbal cannabis is fairly long-standing in these countries, the comparatively low prevalence of use in most countries and their generally smaller population sizes result in retail markets that are much smaller than those in the relatively more affluent and populated western and northern parts of Europe see Figure Indexed trends in number of seizures of cannabis resin and herbal cannabis in 11 eastern EU countries, Trends in numbers of seizures of cannabis resin and herb in these 11 central and eastern European countries present a somewhat different picture from the rest of Europe, characterised by less stability and an overall increase for both products, at least until A similar pattern can be observed in Europe as a whole. However, in the case of cannabis resin seizures, the pattern in the east of the EU differs markedly from the overall European picture, which shows numbers of resin seizures having risen back to nearly pre-pandemic levels in Overall, these trends seem to indicate that cannabis retail markets in the eastern part of the EU are growing, unlike those in most of the rest of Europe. However, the impact of COVID in eastern Europe, particularly on resin, seems to be stronger and longer lasting than in the rest of the continent see Figure Indexed trends in number of seizures of cannabis resin and herbal cannabis in 11 eastern EU countries, Cannabis oil has long been a marginal product on European consumer markets, with the total number of European seizures rarely reaching more than per year since reporting began in These five countries may therefore be viewed as emerging retail markets for cannabis oil in Europe, although several other countries with high prevalence of cannabis use do not report seizures of oil. These findings, together with an increase in the quantity of oil seized see Section Cannabis trafficking and supply: record quantities seized in , could indicate that cannabis oil is slowly gaining popularity among some European consumers. Some of the comparatively newer cannabis consumer products, such as butane hash oil BHO , rosin or cannabis wax, that have become available in Europe in recent years see Figure Cannabis: taxonomy of products traditional and modern are probably manufactured by consumers themselves from their own cannabis crops or from herbal or resin material purchased from dealers. However, some of these products may also be the result of commercial manufacturing in Europe and elsewhere. For instance, there have been seizures of such products at European postal hubs and airports, in parcels and on flights from Canada and the United States. Some of these products have also been seized in the United States on their way to Europe. These seizures usually involve small amounts, weighing a few hundred grams or less, although larger quantities are seized occasionally. For instance, in , a total of almost 58 kilograms of cannabis wax from the United States was seized in Germany. In , some 4. Other products such as edibles and e-cigarette liquids appear to have emerged in Europe more recently. They tend to be manufactured more professionally, often in third countries. The development of novel cannabis consumer products has been particularly dynamic and fast-paced in countries where cannabis has been regulated for recreational use, especially Canada and some parts of the United States. A broad range of products containing semi-synthetic cannabinoids, such as HHC, are available from online shops in some EU countries. Cannabis edibles are foods that are infused with cannabinoids Barrus et al. They can mimic popular brands of foods, particularly sweets and other snack products see Photo Examples of edibles containing THC seized in Sweden in and Box Cannabis marketing methods in France: learning from licit business enterprises. Commercial edibles appear to have become increasingly popular in some North American jurisdictions following cannabis policy changes. While they are usually subject to strict regulations aimed at reducing the potential harms and risks associated with their use, counterfeit, unlicensed and illegal cannabis edibles have nevertheless appeared on North American cannabis markets Health Canada, They are sold on darknet markets, through social media see Section Online distribution of cannabis products and at street level. Of particular concern are recent German federal police reports indicating an increase in the availability of THC-infused edibles, some of which are sold in packages mimicking branded sweets see Boxes Edibles: increased risks of poisoning and Cannabis marketing methods in France: learning from licit business enterprises. Based on the data currently available, it is difficult to estimate the size of the European market for cannabis edibles, or their manufacturing locations and trafficking routes. In particular, North America appears to be an important source. E-liquids liquids used in electronic vaping devices containing concentrates of phytocannabinoids, semi-synthetic cannabinoids and synthetic cannabinoids appear to have become available and increasingly popular among European consumers over the past few years. Included in this category are products containing synthetic cannabinoids mis-sold as containing THC or CBD, which can pose a high risk of poisoning because of their high potency EMCDDA, b, c see Box e-Liquids containing synthetic cannabinoids detected in France. Similar to many other recently emerging cannabis consumer products, cannabis e-liquids and associated products were initially developed in North America, where they are now widely available and popular, particularly among young people Lim et al. In the United States, in the summer of , there was an outbreak of e-cigarette or vaping use-associated lung injury EVALI related to counterfeit products containing deltaTHC, most probably due to contamination with vitamin E acetate. This outbreak resulted in the deaths of at least 68 people and thousands of hospitalisations across the country CDC, ; Duffy et al. However, insufficient information is available to adequately assess the potential toxicity of newer products containing semi-synthetic cannabinoids Meehan-Atrash and Rahman, Most of these appear to have been smuggled in from North America see Box Seizures of cannabis liquids and oils destined for Europe. Cannabis is bought, sold and traded in a variety of ways across Europe using both offline and online methods. Offline methods include the use of dealers in open, semi-open and closed settings. Open markets can be street-based markets May and Hough, ; Skliamis and Korf, while semi-open markets are often located in clubs and other quasi-private settings Tzanetakis, In closed markets business is conducted on a trust basis Potter, Online methods include purchases facilitated via the surface web, social media channels and the darknet. These could be considered semi-open settings, whereby no established relationship is usually required, but buyers have to subscribe or register with channels and platforms to gain access. In online methods, monetary transactions and deliveries may take place without any face-to-face contact, as is especially the case with purchases over the darknet. Sometimes, however, online methods simply facilitate the contact between buyers and sellers, for example via social media, and the exchange of money and drugs might still take place in person Mounteney et al. Evidence indicates that cannabis is relatively frequently shared within peer groups, sometimes without any monetary exchange or in a non-commercial or non-profit manner. This also extends to cannabis resin. Similarly, a study among cannabis coffeeshop visitors in Amsterdam from seven different European countries 4 , investigating how participants usually acquired cannabis in their home countries, found that, in the past 12 months, While the social supply of cannabis seems to be relatively prevalent in the EU, research indicates that the sources from which users acquire their cannabis vary between countries. However, the proportion of participants who reported buying from friends and street dealers differed greatly between the seven countries included in the study. Twenty-one EU countries and Switzerland. The source data for this graphic is available in the source table on this page. Smaller numbers also reported using edibles 8 and cannabis oil 5 Some of these respondents provided detailed information enabling analysis of how herbal cannabis and cannabis resin are retailed in Europe. This finding supports other research indicating the growth of internet-based methods for purchasing drugs Barratt et al. However, the use of these methods appears to differ significantly between countries in Europe Skliamis and Korf, It should be noted that the results of the EWSD cannot readily be generalised to any larger populations. Significant differences among European countries were also apparent in the use of different delivery methods see Table Delivery methods for herbal cannabis and cannabis resin. At the aggregate level, for the 7 EWSD respondents reporting how they usually buy cannabis resin, and how it is delivered to them, the results are broadly similar to those of herbal cannabis see Figures In the last 12 months, how did you usually buy cannabis resin hashish? At the country-level, however, some differences are observable see Table Sources of acquisition for herbal cannabis and cannabis resin. Delivery methods were shown by the EWSD to be fairly consistent between cannabis resin and herbal cannabis at the aggregate level see Figure In the last 12 months, how was the cannabis resin hashish usually delivered to you? As already indicated, a range of sources of acquisition and delivery methods are used for herbal cannabis and cannabis resin in Europe see Tables Sources of acquisition for herbal cannabis and cannabis resin and Delivery methods for herbal cannabis and cannabis resin. The data appear to point to distinct retail markets for herbal cannabis and cannabis resin, both in Europe as a whole and within individual countries, although caution is required when comparing these data, due to small sample sizes in some countries and also because of the relatively small sample size for resin. Nevertheless, the findings suggest that it is important to analyse the herbal cannabis and cannabis resin markets separately Vuolo and Matias, Data from eight darknet markets gathered in Cannazon, Alphabay, ASAP, Cypher, Dark0dereborn, Royal, Versus and World showed a total of 13 unique listings 5 sale offers for cannabis products reported as being shipped from an EU country in To put this in context, while not directly comparable, in a similar scanning exercise conducted in , 10 listings were found for cocaine and 1 for methamphetamine. This includes high-THC products such as concentrates e. However, caution is needed in interpreting these data as neither the number of transactions nor the number of individual sellers can be extrapolated from the number of listings alone. Nonetheless, listings provide a useful indicator of the activity on darknet markets. The typical quantity most frequently observed value of herbal cannabis offered was 5 grams 1 listings , followed by 10 grams 1 and 1 gram The typical price per gram was EUR 14 in 74 listings of 1 gram. In , bulk listings of herbal cannabis were observed see Table Quantity and price details of bulk herbal cannabis listings shipping from EU, The typical quantity of cannabis resin offered in was 5 grams , followed by 10 grams and 1 gram The typical price per gram was EUR 15 in 20 listings of 1 gram. There were 64 bulk listings of cannabis resin observed in However, due to the limited price data available for analysis, caution should be exercised when interpreting these findings. A small proportion of the listings on darknet markets in included cannabis concentrates and edibles. Social media platforms are frequently used to promote and sell cannabis products see forthcoming EU Drug Markets: Drivers and Facilitators , section on Social media and instant messaging apps. Cannabis products have been found to feature prominently on Facebook, where they represent the majority of the drug content advertised for sale, as seen in Denmark, Iceland and Sweden Demant et al. Overall, social media platforms appear to be frequently used to promote drug sales, sometimes using creative photo or video editing or other marketing techniques Geoffroy, ; Paolini and Lepoivre, ; MCP, ; see also Box Cannabis marketing methods in France: learning from licit business enterprises. Cannabis influencers, that is, individuals promoting cannabis products to their followers on social media platforms, have become particularly active on Instagram. While most cannabis influencers appear to be male, there are indications that female influencers are becoming more active on social media Bakken and Harder, This may be part of a broader push towards commercialising cannabis and attempting to sell licensed and unlicensed products to a mainstream audience, in addition to influencing ongoing policy debates. Estimating the size of illicit drug markets is inherently difficult and cannabis is no exception. Nevertheless, because cannabis is the drug most frequently used in Europe and its use generally has a higher level of social acceptance compared to other illicit drugs, there are comparatively more comprehensive and robust data relating to its use. These data enable a more accurate estimation of the size of the illicit market for cannabis. However, this market is becoming increasingly complex due to the emergence of new products, for which data are limited. Thus, any estimate of the size of the illicit cannabis market is restricted to herbal cannabis and cannabis resin. Using the methodology established by the EMCDDA b , it was estimated that cannabis products account for the largest share of the overall illicit drug retail market in the EU, with an estimated value in of at least EUR Out of this total, the illicit market for herbal cannabis was estimated to be worth at least EUR 8. In comparison, the illicit cannabis resin market was estimated to be worth at least EUR 2. This estimate is based on the number of users and their patterns of use, the amount used per year and the average price paid at the retail level. This method, often called a demand-side approach, however, is prone to underestimation due to the misreporting and under-reporting of use Udrisard et al. The basic model used in the estimation process can be expressed in the following simple arithmetic form:. The estimated number of cannabis users was calculated based on prevalence data from general population surveys GPS and categorised according to frequency of use see Box Links between frequency of use and sources of acquiring cannabis. Separate estimates were generated for cannabis resin and herbal cannabis, and, given the high numbers of cannabis users, it was possible to obtain information on the amounts of each product used by different types of users. Individuals were categorised into four different groups according to frequency of cannabis use, as follows:. Taken together, these data were used to estimate the illicit retail market size for herbal cannabis and cannabis resin respectively. There are limitations to this method. For example, for some variables where no data were available, it was necessary to impute values. This included instances when a country had no price data, in which case a simple average of the values for the other countries was used, and when prevalence data was not available for , instead of which the latest available data were used. Occasionally, EU Member States construct their own market size estimates for drugs that are particularly relevant at the national level. For example, Czech authorities have developed an estimate for the market size of methamphetamine, the most prevalent synthetic stimulant used in the country. Based on the latest available data, this illicit cannabis market had an estimated annual turnover of EUR 1. Such national estimates are useful to contextualise the overall EU estimate. In a literature review conducted for this analysis Udrisard et al. Europe featured as a region of focus in two of the studies and nine of the studies looked at cannabis alone. The majority used a demand-side approach, while two employed a supply-side methodology see Box Supply-side approaches to estimating the size of illicit drug markets , and three used a combination of both. As already highlighted, estimating cannabis consumption using wastewater is challenging, and more research is needed in this area, which may improve the use of this method in the future Causanilles et al. Ten of the studies employing the demand-side approach augmented user numbers by drawing on general population surveys and complementary sources to account for under-represented user populations. These include, for example, teenagers aged 15 and under, people with high-risk patterns of use, such as opioid users, or prisoners and homeless populations, all of whom may be excluded, to varying degrees, from GPS but can represent a significant number of cannabis users. All of the demand-side attempts to estimate illicit drug market sizes suffer from under-reporting, whereby people report no use or less frequent use, or do not respond to a representative survey, such as a GPS. Among the 15 papers using survey data, seven applied correction factors for under-reporting in order to provide new prevalence rates Udrisard et al. Data on quantities used also present issues that require a degree of interpretation and making assumptions. For example, while two studies asked questions about how many cannabis joints were smoked, neither asked about the typical amount of cannabis contained in one joint. To fill such data gaps, information on quantities used can be collected via non-representative surveys that specifically target people who use drugs. This is the basis for using data from the European Web Survey on Drugs to develop an EU-level estimate of the illicit cannabis market. It is notable that while some studies considered the issue of cannabis sharing and how this impacted on their market size estimates, it was concluded that there was no real evidence of a global overestimation. While estimates were not revised to account for this potential issue, researchers have strongly recommended further research in this area Udrisard et al. The study conducted for estimating the size of illicit drug markets in the EU concluded that there remains a strong suspicion that demand-based estimates, especially for the drugs most used in Europe, underestimate the real size of these markets Udrisard et al. Nevertheless, the expert consultation that was part of the study confirmed that there are very few alternatives to demand-based approaches for drug market estimates. Overall, further research is needed in this area. Further information is available online. However, respondents from these partner countries are not included in the analysis presented in this report. Consult the list of references used in this module. Homepage Quick links Quick links. GO Results hosted on duckduckgo. Main navigation Data Open related submenu Data. Latest data Prevalence of drug use Drug-induced deaths Infectious diseases Problem drug use Treatment demand Seizures of drugs Price, purity and potency. Drug use and prison Drug law offences Health and social responses Drug checking Hospital emergencies data Syringe residues data Wastewater analysis Data catalogue. Selected topics Alternatives to coercive sanctions Cannabis Cannabis policy Cocaine Darknet markets Drug checking Drug consumption facilities Drug markets Drug-related deaths Drug-related infectious diseases. Recently published Findings from a scoping literature…. Penalties at a glance. Frequently asked questions FAQ : drug…. FAQ: therapeutic use of psychedelic…. Viral hepatitis elimination barometer…. EU Drug Market: New psychoactive…. EU Drug Market: Drivers and facilitators. Statistical Bulletin home. Quick links Search news Subscribe newsletter for recent news Subscribe to news releases. This make take up to a minute. Once the PDF is ready it will appear in this tab. Sorry, the download of the PDF failed. Table of contents Search within the book. Introduction Introduction Key findings and threat assessment Key findings and threat assessment Global context Global context Production Production Trafficking and supply Trafficking and supply Retail markets Retail markets Criminal networks Criminal networks Actions to address current threats and increase preparedness Actions to address current threats and increase preparedness. Search within the book Operator Any match. Exact term match only. Main subject. Target audience. Publication type. EU Drug Market: Cannabis — main page. On this page.
Buying hash Velenje
Buy Marijuana in. Velenje/novo mesto/ptuj/Trbovlje/kamnik/Amsterdam/Rotterdam/the Hague/Maastricht
Buying hash Velenje
Buying hash Velenje
Buy Marijuana themed clothes Products Online in Slovenia
Buying hash Velenje
Buying hash Velenje
Buying hash Velenje
Buying powder online in Villa Gesell
Buying hash Velenje